Results: NSCLC had significantly higher PD-L1 expression compared to SCLC (P = 0.004). There was significant difference in PD-L1 expression between different histologic types in NSCLC (P < 0.001).
There was higher PD-L1 expression in EGFR wild type than in EGFR mutation type (P < 0.001). There was higher PD-L1 expression in ALK mutation than in EGFR mutation (P = 0.005). Longer tumor tissue storage time correlated with lower PD-L1 expression in lung cancer (P < 0.001 for linear trend).
Conclusion: Significant differences in PD-L1 expression were found between SCLC and NSCLC and between different histologic types in NSCLC. EGFR and ALK mutation statuses and tumor tissue storage time may influence PD-L1 expression level. with epidermal growth factor (EGFR) mutation. One meta-analyses reported in 2013 (mutMap) shows that 47.9% among Asian patients with lung adenocarcinoma have EGFR mutation. EGFR mutation plays an important role for predicting effectiveness of the treatment, and prognosis in lung adenocarcinoma patients. In this study we investigated the incidence and the types of EGFR mutation among lung adenocarcinoma patients diagnosed by the department of respiratory medicine in our hospital.
Methods:
We retrospectively investigated the rate and type of EGFR mutation from medical records of 655 patients with lung cancer diagnosed in the department of respiratory medicine in Ishikawa prefectural central hospital from 2012 to 2016.
Results: There were 335 patients diagnosed as adenocarcinoma among 655 patients. There were 100 patients had EGFR mutations (30.1% among adenocarcinoma patients). There were 48 cases with L858R mutation (47.1%) and 35 cases with Exon 19 deletion (34.3%) in EGFR mutations. Overall survival of EGFR mutation positive patients in stage III and IV is significantly longer (49 cases, 32.3 months) than EGFR mutation negative patients (148 cases, 11.6 months) Conclusion: About 30% patients with lung adenocarcinoma patients have EGFR mutations in our retrospective investigation from 2012 to 2016, and the prognosis is better than the patients without EGFR mutations. Methods: Specimens from 3806 NSCLC patients were tested for EGFR mutations. We surveyed the different first-line treatments and their effectiveness in NSCLC patients with exon 20 insertion EGFR mutations.
AP216 EFFECTIVENESS OF TREATMENTS IN ADVANCED NON-SMALL CELL LUNG CANCER WITH EXON 20 INSERTION EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS JENN-YU WU
Results: Of the 3806 patients, 2113 (55.5%) had EGFR mutations, including 85 patients (4.0%) with exon 20 insertion mutations. Effectiveness of different first-line treatments are compared. Pemetrexedcontaining regimens were associated with better progression-free survival (6.2 m vs 2.7 m, P<0.001) and overall survival (28.0 m vs 13.9 m, P = 0.016) than regimens without pemetrexed. TKIs were related to poor response to patients with exon 20 insertions. However, the mutation A763_Y764 insFQEA was associated with favourable response to TKIs. 
